2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
21
Neurofibromatosis 1
19
Neurofibroma, Plexiform
11
Melanoma
11
Lung Neoplasms
8
Neoplasms
7
Neoplasm Metastasis
7
Colorectal Neoplasms
7
Breast Neoplasms
7
Solid Tumours
5
Pancreatic Neoplasms
5
Carcinoma, Hepatocellular
4
Uveal Melanoma
3
Triple Negative Breast Neoplasms
3
Thyroid Neoplasms
3
Rectal Neoplasms
3
Neurofibrosarcoma
3
Gallbladder Neoplasms
3
Colonic Neoplasms
3
Biliary Tract Neoplasms
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Bile Duct Neoplasms
2
Adult Solid Neoplasm
2
Thyroid Diseases
1
Thymoma
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Kaposi
1
Renal Insufficiency
1
Interventions
pembrolizumab
189
Cisplatin
47
Paclitaxel
45
Carboplatin
44
lenvatinib
31
Docetaxel
23
Pemetrexed
21
Fluorouracil
20
Capecitabine
17
Gemcitabine
15
Oxaliplatin
14
Saline Solution
13
Albumin-Bound Paclitaxel
11
130-nm albumin-bound paclitaxel
10
epacadostat
9
Leucovorin
9
Cetuximab
9
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
enzalutamide
5
durvalumab
5
belzutifan
5
Nivolumab
5
Dexamethasone
5
Surgical Procedures, Operative
4
Radiotherapy
4
trifluridine tipiracil drug combination
3
spartalizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
AZD 6244
×
Clear all
NCT03833427
2024-11-07
MK-5618-001
Merck Sharp & Dohme LLC
Phase 1
Terminated
32 enrolled
17 charts